All In Biotech

Drug Trial Radar · NCT01697410

Continuos Terlipressin Infusion in Septic Shock

A Multicenter,Prospective,Randomized,Controlled,Double Blind Study in China to Evaluate the Effect of Terlipressin in Patients With Septic Shock

Last checked: Nov 20, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jan 2013

Primary completion

Jan 2016

Study completion Jan 2016

Sponsor

Lead sponsor
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guangdong Province, Department of Science and Technology; Second Affiliated Hospital, Sun Yat-Sen University; Sixth Affiliated Hospital, Sun Yat-sen University; Chinese PLA General Hospital; Beijing 302 Hospital; Shanghai Changzheng Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Xiangya Hospital of Central South University; Anhui Provincial Hospital; The First Affiliated Hospital of Bengbu Medical University; Guangxi Medical University; Jinling Hospital, China; West China Hospital; Hainan People's Hospital; Xi'an Jiaotong University; China Medical University, China; First People's Hospital of Foshan; ZhuHai Hospital
First posted
Oct 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of terlipressin for treating septic shock.

Conditions

  • Septic Shock

Interventions

  • TerlipressinDrug

    continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure

  • NorepinephrineDrug

    continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day MortalityTime frame: 28-days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Surgical intensive care unit, 1st affiliated hospital of Sun Yat-sen university

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.